Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...

Detailed price information for American Tower Corp (AMT-N) from The Globe and Mail including charting and trades.

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Rybelsus is now available in over ... with the additional rollout of Wegovy globally. At Novo Nordisk, we will continue to focus on commercial execution, the progression of our R&D pipeline ...

A decision is expected in the fourth quarter of 2025.

While several molecules are available in the anti-obesity segment, data shows semaglutide pill Rybelsus from Danish pharma giant Novo Nordisk as the key growth driver of this market. Currently ...

I find Novo's 2-year delayed move into oral GLP-1s uninspiring and unlikely to change investor sentiment meaningfully, considering the performance of Rybelsus ... that Novo Nordisk will maintain ...